Patents by Inventor Duane Burnett

Duane Burnett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM
    Publication number: 20080070889
    Abstract: Disclosed are compounds of the formula wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein. Also disclosed are methods of treating pain, and methods of inhibiting the absorption of cholesterol using a compound of formula I.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: DUANE BURNETT, Brian McKittrick
  • Spirocyclic Azetidinone Compounds and Methods of Use Thereof
    Publication number: 20080070890
    Abstract: The present invention relates to Spirocyclic Azetidinone Compounds, compositions comprising a Spirocyclic Azetidinone Compound and methods for treating or preventing a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease, comprising administering to a patient an effective amount of a Spirocyclic Azetidinone Compound.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: Duane A. Burnett, Brian A. McKittrick
  • AZETIDINE AND AZETIDONE DERIVATIVES USEFUL IN TREATING PAIN AND DISORDERS OF LIPID METABOLISM
    Publication number: 20080070888
    Abstract: Disclosed are compounds of the formula wherein Z1 is —CH2— or —C(O)—, R4 and R5 are carbon chains (and optionally, together can form a C2 bridge), u and v are independently an integer of 0-3 such that there sum is from 3 to 5, and R2 is heteroaryl, and R1 and R3 are as defined herein. Also disclosed are methods of treating pain using a compound of formula I.
    Type: Application
    Filed: September 13, 2007
    Publication date: March 20, 2008
    Inventors: Brian McKittrick, Elizabeth Smith, Chad Bennett, Duane Burnett, Chad Knutson
  • Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
    Publication number: 20070197581
    Abstract: This invention discloses novel gamma secretase inhibitors of the formula: R2 and R3, or R2 and R4, or R3 and R4, together with the atoms to which they are bound, can form a fused cycloalkyl or fused heterocycloalkyl ring. The cycloalkyl ring or the heterocycloalkyl ring can be optionally substituted with one or more substitutents. One or more compounds of formula (I), or formulations comprising such compounds, may be useful, e.g. in treating Alzheimer's Disease.
    Type: Application
    Filed: January 18, 2007
    Publication date: August 23, 2007
    Inventors: Theodros Asberom, Thomas Bara, Chad Bennett, Duane Burnett, Mary Ann Caplen, John Clader, David Cole, Martin Domalski, Hubert Josien, Chad Knutson, Hongmei Li, Mark McBriar, Dmitri Pissarnitski, Li Qiang, Murali Rajagopalan, Thavalakulamgara Sasikumar, Jing Su, Haiqun Tang, Wen-Lian Wu, Ruo Xu, Zhiqiang Zhao
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Publication number: 20070155674
    Abstract: The present invention provides substituted azetidinone compounds, formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject.
    Type: Application
    Filed: February 13, 2007
    Publication date: July 5, 2007
    Applicant: Schering Corporation
    Inventors: Duane Burnett, John Clader
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Publication number: 20070155676
    Abstract: The present invention provides substituted azetidinone compounds, formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject.
    Type: Application
    Filed: February 20, 2007
    Publication date: July 5, 2007
    Applicant: Schering Corporation
    Inventors: Duane Burnett, John Clader
  • Substituted azetidinone compunds, processes for preparing the same, formulations and uses thereof
    Publication number: 20070155675
    Abstract: The present invention provides substituted azetidinone compounds, formulations and processes for preparing the same which can be useful for treating vascular conditions such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols in a subject.
    Type: Application
    Filed: February 13, 2007
    Publication date: July 5, 2007
    Applicant: Schering Corporation
    Inventors: Duane Burnett, John Clader, Wayne Vaccaro
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Patent number: 7235543
    Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: June 26, 2007
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, John W. Clader, Wayne Vaccaro
  • Use of azetidinone compounds
    Publication number: 20070105141
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Application
    Filed: October 25, 2006
    Publication date: May 10, 2007
    Applicant: Schering Corporation
    Inventors: Scott Altmann, Duane Burnett, Harry Davis, Michael Graziano, Maureen Laverty, Xiaorui Yao
  • 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7214691
    Abstract: The present invention discloses compounds of formula I wherein Ar, X, R1 and R11 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: August 23, 2004
    Date of Patent: May 8, 2007
    Assignee: Schering Corporation
    Inventors: Wen-Lian Wu, Duane A. Burnett, Mary Ann Caplen
  • Selective D1/D5 receptor antagonists for the treatment of obesity and CNS disorders
    Patent number: 7211574
    Abstract: The present invention provides compounds, which, are novel antagonists for D1/D5 receptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such D1/D5 receptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: August 27, 2003
    Date of Patent: May 1, 2007
    Assignee: Schering Corporation
    Inventors: Wen-Lian Wu, Duane A. Burnett, William J. Greenlee, Thavalakulamgara K. Sasikumar
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Patent number: 7208486
    Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: April 24, 2007
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, John W. Clader
  • Fused tricyclic mGluR1 antagonists as therapeutic agents
    Publication number: 20070072863
    Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1-R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
    Type: Application
    Filed: August 16, 2006
    Publication date: March 29, 2007
    Inventors: Chad Bennett, Wen-Lian Wu, Duane Burnett
  • Fused tricyclic mGIuR1 antagonists as therapeutic agents
    Publication number: 20070072864
    Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J3, X, Z, and R1, R3, and R4 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
    Type: Application
    Filed: August 16, 2006
    Publication date: March 29, 2007
    Inventors: Chad Bennett, William Greenlee, Chad Knutson, Duane Burnett
  • Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
    Patent number: 7192944
    Abstract: The present invention provides compounds represented by the structural formula (I): or pharmaceutically acceptable isomers, salts, solvates or esters of the compound of Formula (I), wherein each of the substituents is as specified herein, formulations including the above compounds, processes for preparing the same and methods for treating vascular conditions, such as atherosclerosis or hypercholesterolemia, diabetes, obesity, stroke, demyelination and lowering plasma levels of sterols and/or stanols.
    Type: Grant
    Filed: March 3, 2004
    Date of Patent: March 20, 2007
    Assignee: Schering Corp.
    Inventors: Duane A. Burnett, John W. Clader
  • Use of azetidinone compounds
    Patent number: 7144696
    Abstract: The use of azetidinone compounds that are inhibitors of cholesterol absorption as tools for discovering and characterizing proteins involved in trafficking or absorption of cholesterol and/or cholesteryl esters in biological systems is presented. These compounds can serve as tools for competitive binding assays to discover and characterize other chemical agents useful as cholesterol absorption inhibitors. New compounds of the present invention are also highly efficacious inhibitors of cholesterol absorption.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: December 5, 2006
    Assignee: Schering Corporation
    Inventors: Scott W. Altmann, Duane A. Burnett, Harry R. Davis, Jr., Michael P. Graziano, Maureen Laverty, Xiaorui Yao
  • Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
    Patent number: 7109207
    Abstract: The present invention discloses compounds which, are novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: June 26, 2003
    Date of Patent: September 19, 2006
    Assignee: Schering Corporation
    Inventors: Duane A. Burnett, Wen-Lian Wu, Thavalakulamgara K. Sasikumar, Martin S. Domalski
  • mGluR1 Antagonists as therapeutic agents
    Publication number: 20060167029
    Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1-R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
    Type: Application
    Filed: December 13, 2005
    Publication date: July 27, 2006
    Inventors: Julius Matasi, Deen Tulshian, Duane Burnett, Wen-Lian Wu, Peter Korakas, Lisa Silverman, Thavalakulamgara Sasikumar, Li Qiang, Martin Domalski
  • Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
    Patent number: 7030113
    Abstract: The present invention discloses compounds of formula I wherein Ar, Z, m, n, p, R1 and R8 are herein defined, said compounds being novel antagonists for melanin-concentrating hormone (MCH), as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such MCH antagonists as well as methods of using them to treat obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.
    Type: Grant
    Filed: September 30, 2004
    Date of Patent: April 18, 2006
    Assignee: Schering Corporation
    Inventors: Thavalakulamgara K. Sasikumar, Duane A. Burnett
  • mGluR1 antagonists as therapeutic agents
    Publication number: 20060009477
    Abstract: In its many embodiments, the present invention provides tricyclic compounds of formula I (wherein J1-J4, X, and R1—R5 are as defined herein) useful as metabotropic glutamate receptor (mGluR) antagonists, particularly as selective metabotropic glutamate receptor 1 antagonists, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds and compositions to treat diseases associated with metabotropic glutamate receptor (e.g., mGluR1) such as, for example, pain, migraine, anxiety, urinary incontinence and neurodegenerative diseases such Alzheimer's disease.
    Type: Application
    Filed: June 14, 2005
    Publication date: January 12, 2006
    Inventors: Julius Matasi, Deen Tulshian, Duane Burnett, Wen-Lian Wu, Peter Korakas, Lisa Silverman, Thavalakulamgara Sasikumar, Li Qiang, Martin Domalski